‘The Oxford-AstraZeneca vaccine candidate is given to people as two doses, at least one month apart. The trial data, which comes from late-stage studies in the UK, Brazil and South Africa, suggests that the vaccine is 62% effective if people get two full doses, but 90% effective when they get a half-strength version of the first dose. The information was provided in a press release and hasn't been published in a peer-reviewed journal. AstraZeneca and Oxford said they're submitting the results for review and publication.’
Read here (Business Insider, Nov 24, 2020)
